CONTEXT: Just to show that RWR is not all cutting edge biotech, this real-world study report demonstrates both a cost saving and better treatment satisfaction for wound care.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 7
1. “Patient satisfaction also improved for overall wound care experience, exudate control, and comfort, all despite fewer nursing visits.1. “Frequency of dressing changes is a key cost driver for nurse time, materials and dressings in wound management, and is becoming even more important with the changes to care delivery we have seen driven by the pandemic,” said Cathy Dalene, Senior Vice President Global Marketing AWM, Smith+Nephew.”
2. “”As this recent study has shown, ALLEVYN LIFE Dressings with their change indicator, extended wear time, and excellent exudate management can reduce costs and also help encourage patients to become more involved in their care.””
3. “**4,5 The EXUMASK™ Change Indicator helps patients and carers take ownership of wounds,4 whilst simultaneously providing high patient satisfaction as well as saving time through fewer dressing changes.5,6. To learn more about ALLEVYN LIFE dressings please visit Smith+Nephew. Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living.”
4. “For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature.”
5. “Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.”